Video

Data Diversity Initiative: Tackling the Medical Research Data Gap

The data-gap in medical research is well documented, and has serious implications for large sections of the world’s population.

Diseases, treatments and drugs affect people differently according to factors such as race, ethnicity, gender or age, meaning these data gaps in research drastically limit our knowledge to effectively diagnose and treat disease. In the age of digital health, the data-gap can no longer be overlooked if we are to avoid exacerbating existing health inequalities.  

At BenevolentAI, we launched an internal initiative to address this challenge, raise awareness and brainstorm possible solutions to the data diversity problem. We then broadened our scope by engaging with the wider scientific and research community.  

During our inaugural event, we invited a panel of experts to discuss the problem of diversity in medical data, and then invited our audience to participate in an interactive workshop to brainstorm holistic and concrete solutions:  

  • Maria Nelson, Senior Head of Innovation Practice, Digital Catapult  
  • Jackie Hunter, CE Clinical and Strategic Partnerships BenevolentAI  
  • Rob Wilson, Senior Regulatory Consultant, DLRC  
  • Diane Harbison, CEO Decipher Analytics  
  • Dawn Duhaney, Product Manager, Wellcome Trust


More Posts

You Might Also Like

News
BenevolentAI achieves further milestones in AI-enabled target identification collaboration with AstraZeneca
Two additional AI-generated novel targets selected by AstraZeneca for its drug development portfolio, resulting in two milestone payments for BenevolentAI.
Oct 6, 2022
News
Interim results for the six months ended 30 June 2022
Continued operational progress and strengthened financial position provides capital for key value inflection points and continued investment in leading technology platform.
Sep 27, 2022
News
Analyst / Investor Event
BenevolentAI announces that during its analyst / investor event and interim results presentation being held in London today, new information on the Company’s BEN-2293 Phase Ib study results will be disclosed.
Sep 27, 2022
Blog
Building the data foundations to accelerate drug discovery
Mark Davies, BenevolentAI’s SVP Informatics and Data, discusses innovations that enable BenevolentAI to leverage biomedical data in drug discovery.
Sep 22, 2022
News
Analyst / Investor Event and Interim Results
BenevolentAI is pleased to announce the full agenda for its upcoming analyst/investor event and interim results being held in London between 14:00 – 17:00 BST (09:00 – 12:00 ET) on Tuesday, 27 September 2022.
Sep 16, 2022
Video
Text & Data Mining in Drug Discovery: A Conversation with Springer Nature
Hear Mark Davies, SVP Informatics and Data, speak to Springer Nature about how BenevolentAI is leveraging the scientific literature to expedite drug discovery.
Sep 2, 2022